JP2012501327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501327A5 JP2012501327A5 JP2011524992A JP2011524992A JP2012501327A5 JP 2012501327 A5 JP2012501327 A5 JP 2012501327A5 JP 2011524992 A JP2011524992 A JP 2011524992A JP 2011524992 A JP2011524992 A JP 2011524992A JP 2012501327 A5 JP2012501327 A5 JP 2012501327A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- hydrate
- compound
- salt
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 198
- 150000003839 salts Chemical class 0.000 claims description 130
- 239000012453 solvate Substances 0.000 claims description 129
- -1 chloro, cyano, ethoxy Chemical group 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 150000004677 hydrates Chemical class 0.000 claims description 21
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 20
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 150000003857 carboxamides Chemical class 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002346 iodo group Chemical group I* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 6
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- OURDNEYNJXXFAW-UHFFFAOYSA-N 2-[2-[(3,4-diethoxyphenyl)methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CCC2)=C2)C2=C1 OURDNEYNJXXFAW-UHFFFAOYSA-N 0.000 claims description 2
- ZSCIYHDDJFZICO-UHFFFAOYSA-N 2-[2-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CCC2)=C2)C2=C1 ZSCIYHDDJFZICO-UHFFFAOYSA-N 0.000 claims description 2
- XQMAHKURCKRHEI-UHFFFAOYSA-N 2-[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound OC(=O)CC1CCCN(C2=CC=3)C1=CC2=CC=3OCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XQMAHKURCKRHEI-UHFFFAOYSA-N 0.000 claims description 2
- IIOPUDVNOKQNDK-UHFFFAOYSA-N 2-[2-[[3-cyano-5-(trifluoromethoxy)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound OC(=O)CC1CCCN(C2=CC=3)C1=CC2=CC=3OCC1=CC(OC(F)(F)F)=CC(C#N)=C1 IIOPUDVNOKQNDK-UHFFFAOYSA-N 0.000 claims description 2
- HXJHNTSVKACFNI-UHFFFAOYSA-N 2-[2-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound OC(=O)CC1CCCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 HXJHNTSVKACFNI-UHFFFAOYSA-N 0.000 claims description 2
- YYERQLHBQBHYKE-UHFFFAOYSA-N 2-[2-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CCC2)=C2)C2=C1 YYERQLHBQBHYKE-UHFFFAOYSA-N 0.000 claims description 2
- VZAQJICHENMYSC-UHFFFAOYSA-N 2-[4-bromo-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Br)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 VZAQJICHENMYSC-UHFFFAOYSA-N 0.000 claims description 2
- RFHZEVOYOUGNKA-UHFFFAOYSA-N 2-[4-chloro-6-[(3-cyano-4-methoxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1 RFHZEVOYOUGNKA-UHFFFAOYSA-N 0.000 claims description 2
- RWFBHHNEDFDSPE-UHFFFAOYSA-N 2-[4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1 RWFBHHNEDFDSPE-UHFFFAOYSA-N 0.000 claims description 2
- HAEAMGHQKYAHSN-UHFFFAOYSA-N 2-[4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-5-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1C HAEAMGHQKYAHSN-UHFFFAOYSA-N 0.000 claims description 2
- PDNPVIUOUJZEMZ-UHFFFAOYSA-N 2-[4-chloro-6-[[3-chloro-4-(1,3-difluoropropan-2-yloxy)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC1=CC=C(OC(CF)CF)C(Cl)=C1 PDNPVIUOUJZEMZ-UHFFFAOYSA-N 0.000 claims description 2
- ZTJAHQOYCPJNBO-UHFFFAOYSA-N 2-[4-chloro-6-[[4-(cyclopropylmethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1OCC1CC1 ZTJAHQOYCPJNBO-UHFFFAOYSA-N 0.000 claims description 2
- YHDXYXKHTNGYGO-UHFFFAOYSA-N 2-[4-chloro-6-[[4-(fluoromethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC1=CC=C(OCF)C(C(F)(F)F)=C1 YHDXYXKHTNGYGO-UHFFFAOYSA-N 0.000 claims description 2
- KMLYXCLMDMRYDN-UHFFFAOYSA-N 2-[4-chloro-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 KMLYXCLMDMRYDN-UHFFFAOYSA-N 0.000 claims description 2
- RLGFHVZCVPTTLP-UHFFFAOYSA-N 2-[4-chloro-6-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1 RLGFHVZCVPTTLP-UHFFFAOYSA-N 0.000 claims description 2
- HUWYAKMXVLYYCB-UHFFFAOYSA-N 2-[4-cyclobutyl-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=C(OCC=3C=C(C(C4CCCC4)=CC=3)C(F)(F)F)C=C22)C1=C2C1CCC1 HUWYAKMXVLYYCB-UHFFFAOYSA-N 0.000 claims description 2
- QBXWFAZAVUOKML-UHFFFAOYSA-N 2-[4-methyl-6-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2C)C2=C1 QBXWFAZAVUOKML-UHFFFAOYSA-N 0.000 claims description 2
- YSVIGFUSBHVXQF-UHFFFAOYSA-N 2-[6-[(3,4-diethoxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 YSVIGFUSBHVXQF-UHFFFAOYSA-N 0.000 claims description 2
- YROGAKZEXADMCC-UHFFFAOYSA-N 2-[6-[(3-cyano-4-cyclohexylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C#N)=CC=C1C1CCCCC1 YROGAKZEXADMCC-UHFFFAOYSA-N 0.000 claims description 2
- RXTPJDXUECAAGM-UHFFFAOYSA-N 2-[6-[(3-cyano-4-cyclopentylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C#N)=CC=C1C1CCCC1 RXTPJDXUECAAGM-UHFFFAOYSA-N 0.000 claims description 2
- CQJMGIUYXGQKNP-UHFFFAOYSA-N 2-[6-[(3-cyano-4-methoxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 CQJMGIUYXGQKNP-UHFFFAOYSA-N 0.000 claims description 2
- PLHKTXYJCYEKDM-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 PLHKTXYJCYEKDM-UHFFFAOYSA-N 0.000 claims description 2
- XVAKSXTWMLJFSC-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2C)C2=C1 XVAKSXTWMLJFSC-UHFFFAOYSA-N 0.000 claims description 2
- NPNHJHMGCDPLBF-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methylsulfonyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2S(C)(=O)=O)C2=C1 NPNHJHMGCDPLBF-UHFFFAOYSA-N 0.000 claims description 2
- QQYBDDBYWMNMBW-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-5-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1C QQYBDDBYWMNMBW-UHFFFAOYSA-N 0.000 claims description 2
- DSAKGSUGOFICNT-UHFFFAOYSA-N 2-[6-[(4-methylsulfonylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 DSAKGSUGOFICNT-UHFFFAOYSA-N 0.000 claims description 2
- JDLBWMCWMKVHBJ-UHFFFAOYSA-N 2-[6-[(4-pyrazol-1-ylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1)=CC=C1N1C=CC=N1 JDLBWMCWMKVHBJ-UHFFFAOYSA-N 0.000 claims description 2
- QFVBNEUFDXTLNT-UHFFFAOYSA-N 2-[6-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(C(F)(F)F)C=C1C(F)(F)F QFVBNEUFDXTLNT-UHFFFAOYSA-N 0.000 claims description 2
- GJNMLDLOMNJTDO-UHFFFAOYSA-N 2-[6-[[3-chloro-4-(1,3-difluoropropan-2-yloxy)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(OC(CF)CF)C(Cl)=C1 GJNMLDLOMNJTDO-UHFFFAOYSA-N 0.000 claims description 2
- PFPJPOLAMPIPGS-UHFFFAOYSA-N 2-[6-[[3-cyano-5-(trifluoromethoxy)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC(OC(F)(F)F)=CC(C#N)=C1 PFPJPOLAMPIPGS-UHFFFAOYSA-N 0.000 claims description 2
- FEZLNHIXVFQJPD-UHFFFAOYSA-N 2-[6-[[4-(2-methylpropyl)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(CC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 FEZLNHIXVFQJPD-UHFFFAOYSA-N 0.000 claims description 2
- RDLRGCFRXOFKAZ-UHFFFAOYSA-N 2-[6-[[4-(cyclohexylmethyl)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1CC1CCCCC1 RDLRGCFRXOFKAZ-UHFFFAOYSA-N 0.000 claims description 2
- JJIPBGSMNCDBMS-UHFFFAOYSA-N 2-[6-[[4-(cyclopropylmethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1OCC1CC1 JJIPBGSMNCDBMS-UHFFFAOYSA-N 0.000 claims description 2
- IMXFZVFUJJOUHT-UHFFFAOYSA-N 2-[6-[[4-(fluoromethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(OCF)C(C(F)(F)F)=C1 IMXFZVFUJJOUHT-UHFFFAOYSA-N 0.000 claims description 2
- DJWFHSYQGCJOFA-UHFFFAOYSA-N 2-[6-[[4-carbamoyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(C(=O)N)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 DJWFHSYQGCJOFA-UHFFFAOYSA-N 0.000 claims description 2
- WEZSBHGIKFJOED-UHFFFAOYSA-N 2-[6-[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(Cl)C(C(F)(F)F)=C1 WEZSBHGIKFJOED-UHFFFAOYSA-N 0.000 claims description 2
- YYYIRGICSGJFRZ-UHFFFAOYSA-N 2-[6-[[4-cyano-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(C#N)C(C(F)(F)F)=C1 YYYIRGICSGJFRZ-UHFFFAOYSA-N 0.000 claims description 2
- WQUODYAJVRWHCT-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]benzimidazol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=NC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 WQUODYAJVRWHCT-UHFFFAOYSA-N 0.000 claims description 2
- PESLCTHINYVCSC-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 PESLCTHINYVCSC-UHFFFAOYSA-N 0.000 claims description 2
- JHJIYVPIFOAMEO-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-cyclopropyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=C(OCC=3C=C(C(C4CCCC4)=CC=3)C(F)(F)F)C=C22)C1=C2C1CC1 JHJIYVPIFOAMEO-UHFFFAOYSA-N 0.000 claims description 2
- AVDZLJKEGWIFFE-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-ethyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C2C(CC)=C3C(CC(O)=O)CCN3C2=CC=C1OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 AVDZLJKEGWIFFE-UHFFFAOYSA-N 0.000 claims description 2
- YOVAHGXSIQIVHZ-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(F)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 YOVAHGXSIQIVHZ-UHFFFAOYSA-N 0.000 claims description 2
- MVTHLCJGJRSEIS-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-iodo-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(I)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVTHLCJGJRSEIS-UHFFFAOYSA-N 0.000 claims description 2
- OKPOPDROEZSIAG-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C2C(C)=C3C(CC(O)=O)CCN3C2=CC=C1OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 OKPOPDROEZSIAG-UHFFFAOYSA-N 0.000 claims description 2
- LUXNZQWXQVCCSK-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-pyridin-2-yl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=C(OCC=3C=C(C(C4CCCC4)=CC=3)C(F)(F)F)C=C22)C1=C2C1=CC=CC=N1 LUXNZQWXQVCCSK-UHFFFAOYSA-N 0.000 claims description 2
- ZDPMZXPFSLSBPW-UHFFFAOYSA-N 2-[6-[[4-cyclopentyloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1OC1CCCC1 ZDPMZXPFSLSBPW-UHFFFAOYSA-N 0.000 claims description 2
- DEEQOMQGACQZCH-UHFFFAOYSA-N 2-[6-[[4-methoxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 DEEQOMQGACQZCH-UHFFFAOYSA-N 0.000 claims description 2
- BCGUKCVQRODEEB-UHFFFAOYSA-N 2-[6-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 BCGUKCVQRODEEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- RWFBHHNEDFDSPE-MRXNPFEDSA-N 2-[(3r)-4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@@H](CC(O)=O)CC2)=C2Cl)C2=C1 RWFBHHNEDFDSPE-MRXNPFEDSA-N 0.000 claims 1
- XVAKSXTWMLJFSC-GOSISDBHSA-N 2-[(3r)-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@@H](CC(O)=O)CC2)=C2C)C2=C1 XVAKSXTWMLJFSC-GOSISDBHSA-N 0.000 claims 1
- PESLCTHINYVCSC-GOSISDBHSA-N 2-[(3r)-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 PESLCTHINYVCSC-GOSISDBHSA-N 0.000 claims 1
- RWFBHHNEDFDSPE-INIZCTEOSA-N 2-[(3s)-4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@H](CC(O)=O)CC2)=C2Cl)C2=C1 RWFBHHNEDFDSPE-INIZCTEOSA-N 0.000 claims 1
- XVAKSXTWMLJFSC-SFHVURJKSA-N 2-[(3s)-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@H](CC(O)=O)CC2)=C2C)C2=C1 XVAKSXTWMLJFSC-SFHVURJKSA-N 0.000 claims 1
- PESLCTHINYVCSC-SFHVURJKSA-N 2-[(3s)-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C([C@H]1CC(=O)O)CN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 PESLCTHINYVCSC-SFHVURJKSA-N 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 0 C*(CC(CC(O)=O)c1c2*)C[n]1c(cc1)c2c(*)c1OCc1c(*)c(*)c(*)c(*)c1 Chemical compound C*(CC(CC(O)=O)c1c2*)C[n]1c(cc1)c2c(*)c1OCc1c(*)c(*)c(*)c(*)c1 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19031108P | 2008-08-27 | 2008-08-27 | |
| US61/190,311 | 2008-08-27 | ||
| US26951909P | 2009-06-24 | 2009-06-24 | |
| US61/269,519 | 2009-06-24 | ||
| PCT/US2009/004851 WO2010027431A1 (en) | 2008-08-27 | 2009-08-26 | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022889A Division JP2015110641A (ja) | 2008-08-27 | 2015-02-09 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501327A JP2012501327A (ja) | 2012-01-19 |
| JP2012501327A5 true JP2012501327A5 (https=) | 2012-09-20 |
| JP5726737B2 JP5726737B2 (ja) | 2015-06-03 |
Family
ID=41491524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011524992A Active JP5726737B2 (ja) | 2008-08-27 | 2009-08-26 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
| JP2015022889A Abandoned JP2015110641A (ja) | 2008-08-27 | 2015-02-09 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022889A Abandoned JP2015110641A (ja) | 2008-08-27 | 2015-02-09 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8415484B2 (https=) |
| EP (1) | EP2342205B1 (https=) |
| JP (2) | JP5726737B2 (https=) |
| KR (2) | KR101800595B1 (https=) |
| CN (2) | CN105816453B (https=) |
| AU (1) | AU2009288738B9 (https=) |
| BR (1) | BRPI0917923B1 (https=) |
| CA (1) | CA2733671C (https=) |
| CY (1) | CY1117830T1 (https=) |
| EA (1) | EA036955B1 (https=) |
| ES (1) | ES2583630T3 (https=) |
| HR (1) | HRP20160890T1 (https=) |
| HU (1) | HUE031479T2 (https=) |
| IL (2) | IL211107A0 (https=) |
| MX (1) | MX2011002199A (https=) |
| NZ (1) | NZ591001A (https=) |
| PL (1) | PL2342205T3 (https=) |
| PT (1) | PT2342205T (https=) |
| RS (1) | RS54970B1 (https=) |
| SI (1) | SI2342205T1 (https=) |
| SM (1) | SMT201600318B (https=) |
| WO (1) | WO2010027431A1 (https=) |
| ZA (1) | ZA201101524B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033168T2 (en) | 2008-03-17 | 2017-11-28 | Actelion Pharmaceuticals Ltd | Dosage regimen for selective SIP1 receptor agonist |
| EA019252B1 (ru) | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| SI2342205T1 (sl) * | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| WO2011005295A1 (en) * | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| SG183416A1 (en) * | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| CN104478885B (zh) * | 2014-12-12 | 2017-08-01 | 常州大学 | 9‑氨基‑9a‑烯丙基苯并吡咯里西啶生物碱的制备方法 |
| CN104710426B (zh) * | 2014-12-12 | 2017-08-01 | 常州大学 | 苯并吡咯里西啶生物碱及其制备方法和用途 |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2018151834A1 (en) * | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| EP3892616A4 (en) * | 2018-12-06 | 2022-07-27 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND MANUFACTURING METHOD AND APPLICATION OF AN AROMATIC RING DERIVATIVE |
| EP3906235B1 (en) | 2019-01-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| US20220142977A1 (en) * | 2019-01-08 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| WO2021213393A1 (en) * | 2020-04-20 | 2021-10-28 | Zebrapeutics Inc. | Method of treating ship1-mediated diseases using pelorol derivatives |
| CN112812052B (zh) * | 2021-02-02 | 2023-12-01 | 成都阿奇生物医药科技有限公司 | 一种治疗溃疡性结肠炎的化合物及其制备方法和用途 |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL293572A (https=) | 1962-06-07 | |||
| DE2226703A1 (de) | 1972-05-25 | 1973-12-13 | Schering Ag | Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung |
| US4057559A (en) * | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
| US4810699A (en) * | 1987-02-20 | 1989-03-07 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them |
| US4782076A (en) * | 1988-03-01 | 1988-11-01 | American Home Products Corporation | Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use |
| PT95692A (pt) | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| US5221678A (en) | 1990-07-26 | 1993-06-22 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| US5998499A (en) | 1994-03-25 | 1999-12-07 | Dentsply G.M.B.H. | Liquid crystalline (meth)acrylate compounds, composition and method |
| US5776967A (en) * | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
| US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
| US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| NZ515086A (en) | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| WO2002039987A2 (en) | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| US7064217B2 (en) | 2001-01-30 | 2006-06-20 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| EP1375463A4 (en) * | 2001-03-29 | 2009-09-02 | Osaka Gas Co Ltd | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION |
| WO2002092068A1 (en) | 2001-05-10 | 2002-11-21 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| MXPA04002679A (es) | 2001-09-27 | 2004-07-30 | Kyorin Seiyaku Kk | Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos. |
| WO2003059346A1 (en) * | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| US7479504B2 (en) * | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| AU2003218056A1 (en) | 2002-03-01 | 2003-09-16 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| CA2533587A1 (en) | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in sphingosine 1-phosphate signaling |
| AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール |
| MXPA05008531A (es) | 2003-02-11 | 2005-11-17 | Irm Llc | Compuestos biciclicos novedosos y composiciones. |
| US7456157B2 (en) | 2003-02-18 | 2008-11-25 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators |
| MXPA05011539A (es) * | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. |
| CA2523677A1 (en) | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| EP1622860B1 (en) | 2003-04-30 | 2012-02-29 | Novartis AG | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs |
| US20060252741A1 (en) | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2004104205A2 (en) | 2003-05-16 | 2004-12-02 | Merck & Co., Inc. | Enzymatic preparation of chiral indole esters |
| CN1791592B (zh) * | 2003-05-19 | 2012-07-04 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
| ES2558761T3 (es) | 2003-05-19 | 2016-02-08 | Novartis Ag | Compuestos y composiciones inmunosupresores |
| BRPI0410439A (pt) | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| GB0313612D0 (en) | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
| EP1661879A4 (en) * | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF |
| CN1874996B (zh) | 2003-08-28 | 2011-05-18 | 诺瓦提斯公司 | 氨基丙醇衍生物 |
| EP1661881B1 (en) | 2003-08-29 | 2014-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
| CN1874991A (zh) * | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
| EP1661889A4 (en) * | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| WO2005044780A1 (ja) | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| ATE528276T1 (de) * | 2003-12-19 | 2011-10-15 | Ono Pharmaceutical Co | Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| JP2005272453A (ja) * | 2004-02-24 | 2005-10-06 | Sankyo Co Ltd | アミノアルコール化合物 |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| JP4740884B2 (ja) | 2004-02-24 | 2011-08-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制性化合物および組成物 |
| WO2005085214A1 (ja) * | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd | ジアリール置換複素５員環誘導体 |
| GB0405289D0 (en) | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
| TWI344954B (en) | 2004-04-02 | 2011-07-11 | Merck Sharp & Dohme | Asymmetric hydrogenation process |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| CN101014329B (zh) | 2004-07-16 | 2010-09-08 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
| JP2007284350A (ja) * | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| TW200611687A (en) | 2004-07-29 | 2006-04-16 | Sankyo Co | Pharmaceutical compositions used for immunosuppressant |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| US8022225B2 (en) * | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| US20060223866A1 (en) | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| MX2007001661A (es) | 2004-08-13 | 2007-04-23 | Praecis Pharm Inc | Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip). |
| MX2007003371A (es) | 2004-09-23 | 2007-05-07 | Wyeth Corp | Derivados de carbazol y ciclopentaindol para tratar infeccion con virus de hepatitis c. |
| MX2007004262A (es) * | 2004-10-12 | 2008-03-04 | Forbes Medi Tech Res Inc | Compuestos y metodos para tratar resistencia a la insulina y cardiomiopatia. |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| ATE397582T1 (de) | 2004-10-22 | 2008-06-15 | Bioprojet Soc Civ | Neue dicarbonsäurederivate |
| AU2005307718A1 (en) * | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| US20080051418A1 (en) * | 2004-11-26 | 2008-02-28 | Tsuyoshi Maekawa | Arylalkanoic Acid Derivative |
| JP2008522977A (ja) | 2004-12-06 | 2008-07-03 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−リン酸のアリールアミドアナログ |
| EP2592066B1 (en) | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
| WO2006079406A1 (en) | 2005-01-25 | 2006-08-03 | Merck Patent Gmbh | Mesogenic compounds, liquid crystal medium and liquid crystal display |
| AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
| KR20080002850A (ko) | 2005-03-23 | 2008-01-04 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
| BRPI0609668A2 (pt) | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| US7723378B2 (en) | 2005-03-23 | 2010-05-25 | Actelion Pharmaceuticals Ltd. | Hydrogenated benzo (C) thiophene derivatives as immunomodulators |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| TWI418350B (zh) | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ｐｐａｒ調節劑之醫藥組成物的用途 |
| EP1896446A1 (en) | 2005-06-24 | 2008-03-12 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| US20070060573A1 (en) * | 2005-08-10 | 2007-03-15 | Lars Wortmann | Acyltryptophanols |
| WO2007024922A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| JPWO2007037196A1 (ja) | 2005-09-29 | 2009-04-09 | 山本化成株式会社 | インドリン系化合物及びその製造方法 |
| EP1965807A4 (en) * | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| TW200736234A (en) | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
| ATE447568T1 (de) | 2006-01-24 | 2009-11-15 | Actelion Pharmaceuticals Ltd | Neue pyrinderivate |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| AU2007212193A1 (en) | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| TW200806611A (en) | 2006-02-09 | 2008-02-01 | Daiichi Seiyaku Co | Novel amidopropionic acid derivatives and medicine containing the same |
| US20070191371A1 (en) * | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
| BRPI0707873A2 (pt) | 2006-02-15 | 2011-05-10 | Allergan Inc | compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p) |
| CN101460458A (zh) * | 2006-02-15 | 2009-06-17 | 阿勒根公司 | 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物 |
| BRPI0707957A2 (pt) | 2006-02-21 | 2011-05-17 | Univ Virginia Patent Found | composto, e, método para prevenção ou tratamento de uma condição ou sintoma patológico em um mamìfero |
| US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| CA2646430A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| JP2009530389A (ja) | 2006-03-21 | 2009-08-27 | エピックス デラウェア， インコーポレイテッド | Ｓ１ｐ受容体調節化合物及びその使用 |
| JP2007262009A (ja) | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
| MX2008012738A (es) | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| JPWO2007129745A1 (ja) | 2006-05-09 | 2009-09-17 | 第一三共株式会社 | ヘテロアリールアミド低級カルボン酸誘導体 |
| EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| WO2007129473A1 (ja) | 2006-05-09 | 2007-11-15 | Daiichi Sankyo Company, Limited | 二環性アリール誘導体 |
| TW200823182A (en) | 2006-08-01 | 2008-06-01 | Praecis Pharm Inc | Chemical compounds |
| US20080070866A1 (en) | 2006-08-01 | 2008-03-20 | Praecis Pharmaceuticals Incorporated | Chemical compounds |
| JP2009545630A (ja) | 2006-08-04 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | 化合物 |
| JP5188972B2 (ja) * | 2006-08-08 | 2013-04-24 | 杏林製薬株式会社 | アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤 |
| WO2008024196A1 (en) | 2006-08-24 | 2008-02-28 | Praecis Pharmaceuticals Incorporated | Chemical compounds |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| TWI392671B (zh) | 2006-09-07 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 吡啶-４-基衍生物 |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| AU2007292347A1 (en) | 2006-09-07 | 2008-03-13 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity |
| PE20080769A1 (es) | 2006-09-08 | 2008-08-14 | Novartis Ag | Derivados de biaril-sulfonamida |
| MX2009002915A (es) | 2006-09-21 | 2009-03-31 | Actelion Pharmaceuticals Ltd | Derivados de fenilo y su uso como inmunomoduladores. |
| SG177221A1 (en) | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| CL2007003784A1 (es) | 2006-12-21 | 2008-06-27 | Abbott Lab | Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato |
| JP2010515750A (ja) | 2007-01-11 | 2010-05-13 | アラーガン インコーポレイテッド | スフィンゴシン−１−ホスフェート（ｓ１ｐ）受容体アンタゴニスト生物活性を有する６−置換インドール−３−カルボン酸アミド化合物 |
| WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008097819A2 (en) | 2007-02-05 | 2008-08-14 | Smithkline Beecham Corporation | Chemical compounds |
| PT2125797E (pt) | 2007-03-16 | 2014-03-11 | Actelion Pharmaceuticals Ltd | Derivados aminopiridina como agonistas do receptor s1p1/edg1 |
| MX2009010060A (es) | 2007-03-21 | 2010-01-20 | Epix Pharm Inc | Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos. |
| KR20090130062A (ko) | 2007-04-19 | 2009-12-17 | 글락소 그룹 리미티드 | 스핑고신 １―포스페이트 (ｓ１ｐ) 효능제로서 사용하기 위한 옥사디아졸 치환된 인다졸 유도체 |
| EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| WO2009019506A1 (en) | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| MX2010001446A (es) | 2007-08-08 | 2010-03-01 | Merck Serono Sa | Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. |
| UY31468A1 (es) | 2007-11-15 | 2009-07-17 | Derivados bis-(sulfonilamino) en terapia 065 | |
| EP2222668B1 (en) | 2007-12-18 | 2011-11-02 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| AU2009206733A1 (en) * | 2008-01-25 | 2009-07-30 | Arena Pharmaceuticals, Inc. | Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| SI2291080T1 (sl) | 2008-05-14 | 2015-11-30 | The Scripps Research Institute | Novi modulatorji sfingosinskih fosfatnih receptorjev |
| WO2009151621A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151626A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| EA019252B1 (ru) * | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| MX2011008450A (es) | 2009-02-10 | 2011-09-01 | Abbott Lab | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| JP5728487B2 (ja) | 2009-10-29 | 2015-06-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 三環式ヘテロ環化合物 |
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| SG183416A1 (en) | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| EP2598126A2 (en) | 2010-07-30 | 2013-06-05 | Saint Louis University | Methods of treating pain |
-
2009
- 2009-08-26 SI SI200931475A patent/SI2342205T1/sl unknown
- 2009-08-26 BR BRPI0917923-2A patent/BRPI0917923B1/pt active IP Right Grant
- 2009-08-26 PT PT97892103T patent/PT2342205T/pt unknown
- 2009-08-26 RS RS20160577A patent/RS54970B1/sr unknown
- 2009-08-26 KR KR1020177014649A patent/KR101800595B1/ko active Active
- 2009-08-26 JP JP2011524992A patent/JP5726737B2/ja active Active
- 2009-08-26 CN CN201610178764.9A patent/CN105816453B/zh active Active
- 2009-08-26 HU HUE09789210A patent/HUE031479T2/en unknown
- 2009-08-26 AU AU2009288738A patent/AU2009288738B9/en not_active Ceased
- 2009-08-26 NZ NZ591001A patent/NZ591001A/xx not_active IP Right Cessation
- 2009-08-26 ES ES09789210.3T patent/ES2583630T3/es active Active
- 2009-08-26 CA CA2733671A patent/CA2733671C/en active Active
- 2009-08-26 HR HRP20160890TT patent/HRP20160890T1/hr unknown
- 2009-08-26 EP EP09789210.3A patent/EP2342205B1/en active Active
- 2009-08-26 MX MX2011002199A patent/MX2011002199A/es active IP Right Grant
- 2009-08-26 PL PL09789210.3T patent/PL2342205T3/pl unknown
- 2009-08-26 EA EA201170374A patent/EA036955B1/ru not_active IP Right Cessation
- 2009-08-26 US US13/060,477 patent/US8415484B2/en active Active
- 2009-08-26 KR KR1020117006863A patent/KR20110058849A/ko not_active Ceased
- 2009-08-26 CN CN200980142790.4A patent/CN102197038B/zh active Active
- 2009-08-26 WO PCT/US2009/004851 patent/WO2010027431A1/en not_active Ceased
-
2011
- 2011-02-07 IL IL211107A patent/IL211107A0/en unknown
- 2011-02-25 ZA ZA2011/01524A patent/ZA201101524B/en unknown
-
2013
- 2013-03-06 US US13/787,233 patent/US9108969B2/en active Active
-
2014
- 2014-07-30 IL IL233869A patent/IL233869A/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022889A patent/JP2015110641A/ja not_active Abandoned
- 2015-08-04 US US14/817,954 patent/US20150336966A1/en not_active Abandoned
-
2016
- 2016-07-20 CY CY20161100713T patent/CY1117830T1/el unknown
- 2016-09-14 SM SM201600318T patent/SMT201600318B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501327A5 (https=) | ||
| JP6236173B2 (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| JP6063870B2 (ja) | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 | |
| JP2011529049A5 (https=) | ||
| JP2020519589A5 (https=) | ||
| JP6259463B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 | |
| AU2011215638B2 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| HRP20160890T1 (hr) | Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja | |
| CN102869661B (zh) | 抗感染化合物 | |
| EP2114903B1 (en) | Bicyclic pyrimidinones and uses thereof | |
| KR20210086674A (ko) | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 | |
| TW201107316A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| JP2013519724A5 (https=) | ||
| JP2015523329A (ja) | ＲＯＲγ活性を阻害し疾患を治療するためのテトラヒドロナフチリジンおよび関連二環式化合物 | |
| TW201904942A (zh) | 經取代５-氰基吲哚化合物及其用途 | |
| US9512119B2 (en) | Difluoromethylene compound | |
| HRP970432A2 (en) | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives | |
| WO2012080230A1 (en) | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders | |
| JP6893516B2 (ja) | ３−（（ヘテロ−）アリール）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 | |
| EP2247601B1 (en) | Thiazopyrimidinones and uses thereof | |
| TWI291467B (en) | CCR1 antagonists and methods of use therefor | |
| JP2017536409A5 (https=) | ||
| TW200831510A (en) | Compounds | |
| US20200069691A1 (en) | Heterocyclic compounds as hiv protease inhibitors | |
| JP2013507426A5 (https=) |